Pancreatic Cancer Research

ResearcherMoffitt Cancer CenterActive in the last 2 years

Stephen W. Behrman

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-2656-0623; OpenAlex author ID A5061424018. Sources: OpenAlex.

Their work

Papers
25 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
0
Collaborators
86
Papers, trials and grants by year

2012: 3 papers · 2013: 1 paper · 2014: 2 papers · 2015: 2 papers · 2016: none · 2017: 3 papers · 2018: 1 paper · 2019: 4 papers · 2020: 2 papers · 2021: 1 paper · 2022: 2 papers · 2023: 1 paper · 2024: none · 2025: 2 papers · 2026: 1 paper

Papers 25

  1. Outcomes of neoadjuvant chemoradiation versus chemotherapy alone for resected distal pancreatic adenocarcinoma. Last author DOI 10.1016/j.hpb.2026.10.001↗
  2. Current paradigm and futuristic vision on new-onset diabetes and pancreatic cancer research. Co-author DOI 10.3389/fphar.2025.1543112↗
  3. Correction: Current paradigm and futuristic vision on new-onset diabetes and pancreatic cancer research. Co-author DOI 10.3389/fphar.2025.1662270↗
  4. Nationwide analysis of unplanned conversion during minimally invasive distal pancreatectomy for pancreatic adenocarcinoma. Last author DOI 10.1016/j.hpb.2023.08.009↗
  5. Tumor Location in the Pancreatic Tail Is Associated with Decreased Likelihood of Receiving Chemotherapy for Pancreatic Adenocarcinoma. Co-author DOI 10.1007/s11605-022-05381-2↗
  6. Reprogramming of pancreatic adenocarcinoma immunosurveillance by a microbial probiotic siderophore. Co-author DOI 10.1038/s42003-022-04102-4↗
  7. Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. Co-author DOI 10.6004/jnccn.2021.0017↗
  8. The utilization and impact of adjuvant therapy following neoadjuvant therapy and resection of pancreatic adenocarcinoma: does more really matter? Co-author DOI 10.1016/j.hpb.2020.02.011↗
  9. Protein kinase D1 regulates metabolic switch in pancreatic cancer via modulation of mTORC1. Co-author DOI 10.1038/s41416-019-0629-9↗
  10. Molecular Alterations Associated with DNA Repair in Pancreatic Adenocarcinoma Are Associated with Sites of Recurrence. Co-author DOI 10.1007/s12029-018-0073-8↗
  11. Superparamagnetic iron oxide nanoparticles of curcumin enhance gemcitabine therapeutic response in pancreatic cancer. Co-author DOI 10.1016/j.biomaterials.2019.04.005↗
  12. Rising BMI Is Associated with Increased Rate of Clinically Relevant Pancreatic Fistula after Distal Pancreatectomy for Pancreatic Adenocarcinoma. Co-author DOI 10.1177/000313481908501232↗
  13. Pancreatic Adenocarcinoma, Version 1.2019. Co-author DOI 10.6004/jnccn.2019.0014↗
  14. Clinical significance of MUC13 in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.hpb.2017.12.003↗
  15. Restitution of Tumor Suppressor MicroRNA-145 Using Magnetic Nanoformulation for Pancreatic Cancer Therapy. Co-author DOI 10.1007/s11605-016-3222-z↗
  16. MUC13 interaction with receptor tyrosine kinase HER2 drives pancreatic ductal adenocarcinoma progression. Co-author DOI 10.1038/onc.2016.218↗
  17. Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. Co-author DOI 10.6004/jnccn.2017.0131↗
  18. Nanoparticle formulation of ormeloxifene for pancreatic cancer. Co-author DOI 10.1016/j.biomaterials.2015.02.082↗
  19. Ormeloxifene suppresses desmoplasia and enhances sensitivity of gemcitabine in pancreatic cancer. Co-author DOI 10.1158/0008-5472.can-14-2397↗
  20. MicroRNA-145 targets MUC13 and suppresses growth and invasion of pancreatic cancer. Co-author DOI 10.18632/oncotarget.2281↗
  21. Pancreatic adenocarcinoma, version 2.2014: featured updates to the NCCN guidelines. Co-author DOI 10.6004/jnccn.2014.0106↗
  22. miRNA profiling in pancreatic cancer and restoration of chemosensitivity. Co-author DOI 10.1016/j.canlet.2012.10.008↗
  23. Micellar delivery of cyclopamine and gefitinib for treating pancreatic cancer. Co-author DOI 10.1021/mp3002792↗
  24. Role of miRNA and cancer stem cells in chemoresistance and pancreatic cancer treatment. Co-author DOI 10.1517/17425247.2012.722079↗
  25. Pancreatic Adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines. Co-author DOI 10.6004/jnccn.2012.0073↗

Closest collaborators

The 25 strongest of 86 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Murali Mohan Yallapu · 11 shared papers, 2014–2025 · strength 1.12
  2. Subhash C. Chauhan · 11 shared papers, 2014–2025 · strength 1.12
  3. Sheema Khan · 11 shared papers, 2014–2025 · strength 1.12
  4. Paxton Vandiver Dickson · 5 shared papers, 2019–2023 · strength 0.71
  5. Meena Jaggi · 9 shared papers, 2014–2022 · strength 0.65
  6. Evan Scott Glazer · 4 shared papers, 2019–2022 · strength 0.49
  7. Zachary E. Stiles · 4 shared papers, 2018–2023 · strength 0.49
  8. Swati Dhasmana · 2 shared papers, 2025 · strength 0.47
  9. Shabia Shabir · 2 shared papers, 2025 · strength 0.47
  10. Anupam Dhasmana · 2 shared papers, 2025 · strength 0.47
  11. Russell Moreland · 2 shared papers, 2025 · strength 0.47
  12. Justin A. Drake · 3 shared papers, 2019–2022 · strength 0.39
  13. Devanshi D. Patel · 1 shared paper, 2026 · strength 0.39
  14. Sonam Kumari · 4 shared papers, 2017–2022 · strength 0.38
  15. Mohammed Sikander · 4 shared papers, 2014–2022 · strength 0.29
  16. Bilal Bin Hafeez · 3 shared papers, 2017–2022 · strength 0.26
  17. William G. Hawkins · 5 shared papers, 2012–2021 · strength 0.24
  18. Andrew H. Ko · 5 shared papers, 2012–2021 · strength 0.24
  19. Brian G. Czito · 5 shared papers, 2012–2021 · strength 0.24
  20. Robert A. Wolff · 5 shared papers, 2012–2021 · strength 0.24
  21. Eric K. Nakakura · 5 shared papers, 2012–2021 · strength 0.24
  22. Mokenge Peter Malafa · 5 shared papers, 2012–2021 · strength 0.24
  23. Brian Matthew Wolpin · 5 shared papers, 2012–2021 · strength 0.24
  24. Margaret A. Tempero · 5 shared papers, 2012–2021 · strength 0.24
  25. Al B. Benson · 5 shared papers, 2012–2021 · strength 0.24

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.